Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Am Soc Nephrol. 2002 Jan;13(1):134-41.

2.

Adiponectin and cardiovascular outcomes among hemodialysis patients.

Abdallah E, Waked E, Nabil M, El-Bendary O.

Kidney Blood Press Res. 2012;35(4):247-53. doi: 10.1159/000334649. Epub 2012 Jan 26.

3.

Adiponectin in essential hypertension.

Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Nephrol. 2002 Sep-Oct;15(5):507-11.

PMID:
12455716
4.

Plasma adiponectin levels for prediction of cardiovascular risk among hemodialysis patients.

El-Shafey EM, Shalan M.

Ther Apher Dial. 2014 Apr;18(2):185-92. doi: 10.1111/1744-9987.12065. Epub 2013 Jul 3.

PMID:
24720410
5.

Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G.

Nephrol Dial Transplant. 2004 Aug;19 Suppl 5:V67-72. Review.

PMID:
15284363
6.

Adiponectin levels and atherosclerotic risk factors in pediatric chronic peritoneal dialysis patients.

Bakkaloglu SA, Buyan N, Funahashi T, Pasaoglu H, Elhan AH, Hasanoglu E, Soylemezoglu O.

Perit Dial Int. 2005 Jul-Aug;25(4):357-61.

PMID:
16022092
7.

Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.

Díez JJ, Iglesias P, Fernández-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, Codoceo R, Selgas R.

Clin Endocrinol (Oxf). 2005 Feb;62(2):242-9.

PMID:
15670203
8.

Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study.

Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D; MMKD Study Group.

J Am Soc Nephrol. 2005 Apr;16(4):1091-8. Epub 2005 Mar 2.

9.

Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology.

Beige J, Heipmann K, Stumvoll M, Körner A, Kratzsch J.

Expert Opin Ther Targets. 2009 Feb;13(2):163-73. doi: 10.1517/14728220802658481 . Review.

PMID:
19236235
10.

Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients.

Zoccali C, Tripepi G, Cambareri F, Catalano F, Finocchiaro P, Cutrupi S, Pizzini P, Testa A, Spoto B, Panuccio V, Enia G, Mallamaci F.

J Ren Nutr. 2005 Jan;15(1):125-30. Review.

PMID:
15648021
11.

Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function.

Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D.

Nephrol Dial Transplant. 2005 Jan;20(1):129-34. Epub 2004 Dec 7.

PMID:
15585515
12.

Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease.

Amira OC, Naicker S, Manga P, Sliwa K, Mia A, Raal F, Crowther NJ, Immelman RA, Olorunju S.

Hemodial Int. 2012 Jan;16(1):59-68. doi: 10.1111/j.1542-4758.2011.00622.x.

PMID:
22099423
13.

Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis.

Tsao YT, Hsu YJ, Chu NF, Lai CH, Chiu JS, Lin SH.

J Nephrol. 2008 Sep-Oct;21(5):744-52.

PMID:
18949730
14.

Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status.

Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, Piloni G, Buccianti G, Catapano AL.

Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):56-63. doi: 10.1016/j.numecd.2009.01.011. Epub 2009 Apr 9.

PMID:
19359150
15.

Plasma adiponectin concentrations in patients with chronic renal failure: relationship with metabolic risk factors and ischemic heart disease.

Tentolouris N, Doulgerakis D, Moyssakis I, Kyriaki D, Makrilakis K, Kosmadakis G, Stamatiadis D, Katsilambros N, Stathakis C.

Horm Metab Res. 2004 Oct;36(10):721-7.

PMID:
15523599
16.

Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease.

Hajer GR, van der Graaf Y, Olijhoek JK, Edlinger M, Visseren FL.

Am Heart J. 2007 Oct;154(4):750.e1-7.

PMID:
17893004
17.

Circulating adiponectin level is associated with major adverse cardiovascular events in type 2 diabetic patients with coronary artery disease.

Hung WC, Wang CP, Lu LF, Yu TH, Chiu CA, Chung FM, Chen HJ, Houng JY, Shin SJ, Lee YJ.

Endocr J. 2010;57(9):793-802. Epub 2010 Aug 31.

18.

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure.

Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M.

J Intern Med. 2003 Aug;254(2):132-9.

19.

Plasma adiponectin is related to other cardiovascular risk factors in nondiabetic Korean men with CAD, independent of adiposity and cigarette smoking: cross-sectional analysis.

Kim OY, Koh SJ, Jang Y, Chae JS, Kim JY, Kim HJ, Cho H, Lee JH.

Clin Chim Acta. 2006 Aug;370(1-2):63-71. Epub 2006 Mar 10.

PMID:
16530178
20.

Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.

Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C.

J Nephrol. 2004 May-Jun;17(3):405-10.

PMID:
15365961

Supplemental Content

Support Center